Payment Policies to Manage Drug Costs

Drug spending

© The Pew Charitable Trusts

U.S. policymakers and patients continue to grapple with rising pharmaceutical spending, which accounted for $310 billion in 2015, an increase of almost 9 percent from the previous year. And costs are expected to continue to rise as high-priced brand-name and specialty medications hit the market. New branded drugs accounted for $24 billion in spending in 2015, while Medicare costs for specialty medications jumped to $33 billion, more than triple what they were in 2010.

Americans spend twice as much on prescription drugs compared to people in other high-income countries. While U.S. payers have struggled to rein in drug costs, health care payers abroad have used a variety of payment and coverage policies to more effectively manage drug spending.

A new report from The Pew Charitable Trusts examines six policies that other countries use to better manage pharmaceutical costs. The report—Payment Policies to Manage Pharmaceutical Costs: Insights From Other Countries”—finds that:

  • External benchmarking—or determining how much to pay for a drug by using a formula that takes into account what other countries pay—could lead to short-term cost savings in Medicare. Over a longer period of time, however, the effect of this policy could diminish as drugmakers increase list prices across the world and grant larger confidential discounts and rebates to hide actual prices being paid.
  • Internal benchmarking—or setting a payment rate for a drug based on the cost of clinically comparable products—could significantly reduce Medicare costs for drugs with comparable therapeutic alternatives.
  • Value-based benchmarking—or setting a price based on a drug’s effectiveness—could help reduce the use of high-cost drugs that offer minimal additional benefits compared with other available therapies.
  • Restricting off-label prescribing—or forbidding the use of medicines for purposes other than those approved by regulatory authorities—could produce savings when employed to restrict use of drugs for which lower-cost, Food and Drug Administration-approved alternatives exist. However, it is unclear what effect off-label prescribing restrictions could have on health outcomes.
  • Payer-seller agreements—in which payers negotiate with pharmaceutical companies to reduce drug prices through discounts or rebates—have had a sizable effect on prices in many countries. The large number of payers in the United States, however, could potentially limit negotiating power and the ability to attain significant discounts. Removing some restrictions on payers’ ability to negotiate—such as formulary requirements in the Medicare program—could increase savings.  
  • Denying coverage for medicines deemed unaffordable could reduce costs, but this approach would face significant sociocultural and legal barriers in the United States. Although reimbursement decisions in the United States can take a drug’s cost into consideration when therapeutic alternatives exist, there are few mechanisms for denying payment for an effective medicine based on price alone.

There is significant momentum in Congress and throughout federal and state governments and private payers to address the issue of high drug costs. Payers and policymakers could benefit from reviewing approaches used in other countries to consider whether similar tools and policies could be adopted or adapted for use in the United States.

Allan Coukell directs health programs at Pew. Chuck Shih works on the drug spending research initiative. 

Spotlight on Mental Health

Drug spending report
Drug spending report

Payment Policies to Manage Pharmaceutical Costs

Insights from other countries

Quick View

In recent years, the high cost of prescription drugs in the United States has been the subject of much public discussion. While attention has been focused on a few instances of what critics see as the most outrageous price increases, policymakers should also recognize that Americans spend twice as much per person on prescription drugs as do people in other high-income countries. Clearly, the problem of high drug costs in the U.S. extends far beyond a handful of extreme examples.

Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.

Explore Pew’s new and improved
Fiscal 50 interactive

Your state's stats are more accessible than ever with our new and improved Fiscal 50 interactive:

  • Maps, trends, and customizable charts
  • 50-state rankings
  • Analysis of what it all means
  • Shareable graphics and downloadable data
  • Proven fiscal policy strategies


Welcome to the new Fiscal 50

Key changes include:

  • State pages that help you keep track of trends in your home state and provide national and regional context.
  • Interactive indicator pages with highly customizable and shareable data visualizations.
  • A Budget Threads feature that offers Pew’s read on the latest state fiscal news.

Learn more about the new and improved Fiscal 50.